Atossa Therapeutics, Inc.
ATOS
$5.16
-$0.34-6.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 36.05% | 9.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.62% | 2.33% | |||
| Operating Income | -23.62% | -2.33% | |||
| Income Before Tax | -25.83% | -3.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.83% | -3.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.83% | -3.19% | |||
| EBIT | -23.62% | -2.33% | |||
| EBITDA | -23.63% | -2.34% | |||
| EPS Basic | -25.83% | -3.20% | |||
| Normalized Basic EPS | -25.84% | -3.19% | |||
| EPS Diluted | -25.83% | -3.20% | |||
| Normalized Diluted EPS | -25.84% | -3.19% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||